Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,569 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
Interventions: Basic Skin Care, Active Skin Care; Other
Lead sponsor: DeNova Research; Other
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: MarzAA; Biological
Lead sponsor: Catalyst Biosciences; Industry
Eligibility: 12 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia

Conditions: Tuberculosis
Interventions: rifapentine, rifapentine and moxifloxacin, control; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 12 Years and older
Enrollment: 2,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: San Francisco, California • New York, New York • Fort Worth, Texas + 2 more

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Germ Cell Tumors
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 15 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Indianapolis, Indiana • Muncie, Indiana • St Louis, Missouri + 3 more

Conditions: Presbycusis, Aging, Hearing Loss
Interventions: Auditory training program, Sham Comparator: Active Control; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 55 Years to 79 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions: MIP Protocol; Behavioral
Lead sponsor: The National Center on Addiction and Substance Abuse at Columbia University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Cardiovascular Diseases, Metabolic Disease, High-intensity Interval Training
Interventions: high-intensity interval training intervention; Other
Lead sponsor: Syracuse University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatocellular Carcinoma
Interventions: Lenvatinib, Transcatheter Arterial Chemoembolization; Drug · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HSV-2
Interventions: AIC316, Placebo; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more

Conditions: Type 2 Diabetes Mellitus With Hypoglycemia, Aging, Patient Activation
Interventions: Prepare for Your Diabetes Care, Usual Care; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 75 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Oakland, California

Conditions: Knee Osteoarthritis
Interventions: KneeBRIGHT System, Control Exercise; Device · Other
Lead sponsor: Barron Associates, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pain, Postoperative
Interventions: Twin block, iPill dispenser; Drug · Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention C Daridorexant, Intervention C Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program; Procedure · Drug · Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab, Placebo; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more

Conditions: CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
Interventions: Scrambler Therapy, Questionnaire and Physical Exam; Device · Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions: CCH-aaes, Antifibrinolytic Agent; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 13
States / cities: Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more

Conditions: HIV-1 Infection
Interventions: Vesatolimod, Placebo, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more

Conditions: Hepatitis C
Interventions: Use of Tappt App; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Gastroparesis
Interventions: Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Redwood City, California

Search by objective public record fields.

A Study to Examine the Effects of Cosmeceutical Therapy in Subjects Undergoing Full Facial Rejuvenation

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

At-home Auditory Training Clinical Trial

Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder

HIIT Effects on Cardiometabolic Health

Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

Prepare for Your Diabetes Care

Knee Biofeedback Rehabilitation Through Game Therapy

Reducing Opioid Use and Misuse After Wisdom Molar Extractions

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

HCV Tappt Adherence Study

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Study to Intervene With Nutrition for Gastroparesis